Healthcare
Cancer, CNS & Cardiovascular Biomarkers: Players, products and prospects
| Publication Date | August 2008 |
| Publisher | Espicom |
| Product Type | Report |
| Pages | 352 |
| ISBN Number | not applicable |
| Product Code | ESP01099 |
Summary
Over 350 information-packed pages providing
Forecasts of biomarker market value and therapy share to 2015
Detailed analysis of the products and potential of companies active in each sector
- 40 Cancer
- 29 CNS
- 34 Cardiovascular
Major biomarker approaches include
- Proteomics
- RNA & MicroRNA
- DNA
- Metabolic
- Electrophysiology
Imaging By 2015, the biomarker market is forecast to be worth over US$20 billion as the cardiovascular and CNS biomarker market segments begin to mature with the launch of a number of diagnostic tests to guide the treatment of neuropsychiatric and neurodegenerative diseases.
This new 3-volume report provides a comprehensive analysis of the major therapy areas which are driving growth, along with a critical assessment of the companies involved.
Unique analysis and scoring
To provide commercial and industry managers with qualified insight to the corporate landscape, the report provides a unique assessment and scoring system for each company covering:
- Biomarker technology
- Association/clinical studies
- Management strategy
- Application & potential
Contents
- Executive Summary
- Figure1: Growth In Biomarker Market 2007-2015
- What Are Biomarkers?
- Why Are They Important?
- Figure 2: Potential Impact Of Biomarkers On Disease Pathways
- What Technologies Are Involved?
- What Impact Will Biomarkers Have On R&d?
- Figure 3: Potential Impact Of Biomarkers On R&d
- Who Are The Major Biomarker Players And In What Research Area?
- Cancer Biomarker Companies
- Cardiovascular Biomarker Companies
- Cns Biomarkers Companies
- Company Analysis Criteria
- Biomarker Technology & Platforms
- Association/Clinical Studies
- Management Strategy
- Application & Potential
- Cancer Market & Revenues
- Market Revenues - Global
- Figure 1: Global Cancer Drugs Sales (2007)
- Market Revenues - Leading Brands
- Figure 2: Leading Cancer Brands (2007)
- Market Revenues - Leading Players
- Figure 3: Top 10 Oncology Players (2007 Revenues)
- Cancer Epidemiology, Diagnosis, Screening & Treatment
- Epidemiology
- Table 1: Cancer Statistics For Four Most Common Cancers, 2008
- Diagnosis
- Screening
- Table 2: Cancer Screening
- Current & Future Treatment
- Future Treatment
- Figure 4: Anticancer Drugs In Clinical Development
- Market Revenues - Global
- Cancer Biomarkers
- Cancer Biomarker R&d
- Table 3: Types Of Biomarker
- Known Cancer Biomarkers
- Table 4: Commercially Available Known Cancer Biomarker Diagnostics
- Probable And Possible Valid Cancer Biomarkers
- Table 5: Probable Cancer Biomarkers Diagnostics
- Table 6: Possible Cancer Biomarkers Diagnostics
- Cancer Biomarker Opportunities & Challenges
- Opportunities
- Challenges
- Cancer Biomarker R&d
- Biomarker Market
- Biomarker Market Revenues - Global
- Figure 8: Global Biomarker Sales In 2007
- Cancer Biomarker Market Revenues - Global
- Figure 9: Global Cancer Biomarker Sales In 2007
- Section Name Cancer, Cns & Cardiovascular Biomarkers: Players, Products And Prospects
- Future Biomarker Market Revenues - Global
- Figure 10: Global Biomarker Sales In 2015
- Future Cancer Biomarker Market Revenues - Global
- Figure 11: Global Cancer Biomarker Sales In 2015
- Biomarker Market Revenues - Global
- Cancer Biomarker Trends
- Table 7: Recent Deals In Oncology Biomarkers
- Pharma And Specialty Pharma Deals
- Collaborations With Service Providers
- Collaborations With Academics And Consortia
- Biomarker Analysis
- Dna Biomarkers
- Rna And Microrna Biomarkers
- Proteomic Biomarkers
- Key Biomarker Companies Analysed
- Key Biomarker Evaluation Criteria
- Cancer Biomarker- Company Analysis
- Abbott Diagnostics
- Biomarker Novelty & Technology Platform
- Figure 12: Abbott''s Urovysion Bladder Cancer Test
- Association Studies/Clinical Data
- Pivotal Trial
- Table 7: Comparison Of Urovysion Vs Cystoscopy/Histology For Detection Of Bladder Cancer Recurrence By Stage And Grade*
- Management Strategy
- Application & Market Potential
- Biomarker Analysis
- Affymetrix
- Biomarker Novelty & Technology Platform
- Figure 13: Affymetrix'' Approach To Biomarker Discovery, Validation And Clinical Utility Applications
- Association Studies/Clinical Data
- Management Strategy
- Application & Market Potential
- Biomarker Analysis
- Agendia Bv
- Biomarker Novelty & Technology Platform
- Association Studies/Clinical Data
- Figure 14: Mammaprint Profile Vs Nih Consensus Criteria
- Management Strategy
- Application & Market Potential
- Biomarker Analysis
- Altheadx
- Biomarker Novelty & Technology Platform
- Association Studies/Clinical Data
- Management Strategy
- Application & Market Potential
- Biomarker Analysis
- Aveo Pharmaceuticals
- Biomarker Novelty & Technology Platform
- Association Studies/Clinical Data
- Management Strategy
- Application & Market Potential
- Biomarker Analysis
- Cancer, Cns & Cardiovascular Biomarkers: Players, Products And Prospects Section Name
- Aviaradx
- Biomarker Novelty & Technology Platform
- Association Studies/Clinical Data
- Management Strategy
- Application & Market Potential
- Biomarker Analysis
- Bg Medicine
- Biomarker Novelty & Technology Platform
- Association Studies/Clinical Data
- Management Strategy
- Figure 15: Bg Medicines Biomarker Programme
- Application & Market Potential
- Biomarker Analysis
- Beckman Coulter
- Biomarker Novelty & Technology Platform
- Association Studies/Clinical Data
- Management Strategy
- Application & Market Potential
- Biomarker Analysis
- Biocurex
- Biomarker Novelty & Technology Platform
- Association Studies/Clinical Data
- Management Strategy
- Application & Market Potential
- Biomarker Analysis
- Biomedical Diagnostics
- Biomarker Novelty & Technology Platform
- Association Studies/Clinical Data
- Management Strategy
- Application & Market Potential
- Biomarker Analysis
- Biomerica
- Biomarker Novelty & Technology Platform
- Association Studies/Clinical Data
- Management Strategy
- Application & Market Potential
- Biomarker Analysis
- Bruker Daltonics
- Biomarker Novelty & Technology Platform
- Association Studies/Clinical Data
- Management Strategy
- Application & Market Potential
- Biomarker Analysis
- Caprion Proteomics
- Biomarker Novelty & Technology Platform
- Association Studies/Clinical Data
- Management Strategy
- Application & Market Potential
- Biomarker Analysis
- Clinical Data
- Biomarker Novelty & Technology Platform
- Section Name Cancer, Cns & Cardiovascular Biomarkers: Players, Products And Prospects
- Association Studies/Clinical Data
- Management Strategy
- Application & Market Potential
- Biomarker Analysis
- Celera
- Biomarker Novelty & Technology Platform
- Association Studies/Clinical Data
- Management Strategy
- Application & Market Potential
- Biomarker Analysis
- Dako Denmark A/S
- Biomarker Novelty & Technology Platform
- Association Studies/Clinical Data
- Management Strategy
- Application & Market Potential
- Biomarker Analysis
- Dxs Ltd
- Biomarker Novelty & Technology Platform
- Association Studies/Clinical Data
- Management Strategy
- Application & Market Potential
- Biomarker Analysis
- Epigenomics Ag
- Biomarker Novelty & Technology Platform
- Association Studies/Clinical Data
- Management Strategy
- Application & Market Potential
- Biomarker Analysis
- Epistem Plc
- Biomarker Novelty & Technology Platform
- Figure 16: Epistem''s Biomarker Drug Development Programme
- Association Studies/Clinical Data
- Management Strategy
- Application & Market Potential
- Biomarker Analysis
- Genenews
- Biomarker Novelty & Technology Platform
- Figure 17: Genenews'' Sentinel Principle
- Association Studies/Clinical Data
- Management Strategy
- Application & Market Potential
- Biomarker Analysis
- Fujirebio Diagnostics, Inc
- Biomarker Novelty & Technology Platform
- Association Studies/Clinical Data
- Management Strategy
- Application & Market Potential
- Biomarker Analysis
- Genomic Health
- Biomarker Novelty & Technology Platform
- Figure 18: Oncotype Dx Test For Invasive Breast Cancer
- Cancer, Cns & Cardiovascular Biomarkers: Players, Products And Prospects Section Name
- Association Studies/Clinical Data
- Management Strategy
- Application & Market Potential
- Biomarker Analysis
- Gen-Probe
- Biomarker Novelty & Technology Platform
- Association Studies/Clinical Data
- Management Strategy
- Application & Market Potential
- Biomarker Analysis
- Genzyme Genetics
- Biomarker Novelty & Technology Platform
- Association Studies/Clinical Data
- Management Strategy
- Application & Market Potential
- Biomarker Analysis
- Intergenetics
- Biomarker Novelty & Technology Platform
- Association Studies/Clinical Data
- Management Strategy
- Application & Market Potential
- Biomarker Analysis
- Ipsogen Therapeutics
- Biomarker Novelty & Technology Platform
- Association Studies/Clinical Data
- Management Strategy
- Figure 19: Oncotype Dx Test For Invasive Breast Cancer
- Application & Market Potential
- Biomarker Analysis
- Laboratory Corporation Of America
- Biomarker Novelty & Technology Platform
- Association Studies/Clinical Data
- Management Strategy
- Application & Market Potential
- Biomarker Analysis
- Matritech
- Biomarker Novelty & Technology Platform
- Association Studies/Clinical Data
- Management Strategy
- Application & Market Potential
- Biomarker Analysis
- Monogram Biosciences
- Biomarker Novelty & Technology Platform
- Figure 20: Veratag Assay
- Association Studies/Clinical Data
- Figure 21: Veratag Clinical Data: Bordet Cohort
- Management Strategy
- Application & Market Potential
- Biomarker Analysis
- Orion Genomics
- Biomarker Novelty & Technology Platform
- Section Name Cancer, Cns & Cardiovascular Biomarkers: Players, Products And Prospects
- Figure 22: Orion''s Methylscope
- Association Studies/Clinical Data
- Management Strategy
- Application & Market Potential
- Biomarker Analysis
- Oxford Genome Biosciences (Uk) Ltd
- Biomarker Novelty & Technology Platform
- Association Studies/Clinical Data
- Management Strategy
- Application & Market Potential
- Biomarker Analysis
- Power3 Medical Products
- Biomarker Novelty & Technology Platform
- Association Studies/Clinical Data
- Management Strategy
- Figure 23: Powder3''s Business Strategy
- Application & Market Potential
- Biomarker Analysis
- Predictive Biosciences
- Biomarker Novelty & Technology Platform
- Association Studies/Clinical Data
- Management Strategy
- Application & Market Potential
- Biomarker Analysis
- Provista Life Sciences
- Biomarker Novelty & Technology Platform
- Association Studies/Clinical Data
- Management Strategy
- Application & Market Potential
- Biomarker Analysis
- Quest Diagnostics
- Biomarker Novelty & Technology Platform
- Association Studies/Clinical Data
- Management Strategy
- Application & Market Potential
- Biomarker Analysis
- Roche Diagnostics
- Biomarker Novelty & Technology Platform
- Figure 24: Diagnostic Marker Candidate To A Product
- Association Studies/Clinical Data
- Figure 25: Biomarkers Distinguish Leukaemia Subclasses
- Management Strategy
- Application & Market Potential
- Biomarker Analysis
- Superarray Bioscience Corporation
- Biomarker Novelty & Technology Platform
- Association Studies/Clinical Data
- Management Strategy
- Application & Market Potential
- Biomarker Analysis
- Third Wave Technologies
- Cancer, Cns & Cardiovascular Biomarkers: Players, Products And Prospects Section Name
- Biomarker Novelty & Technology Platform
- Association Studies/Clinical Data
- Management Strategy
- Application & Market Potential
- Biomarker Analysis
- Upstream Biosciences
- Biomarker Novelty & Technology Platform
- Association Studies/Clinical Data
- Management Strategy
- Application & Market Potential
- Biomarker Analysis
- Veridex, Llc
- Biomarker Novelty & Technology Platform
- Association Studies/Clinical Data
- Management Strategy
- Application & Market Potential
- Biomarker Analysis
- Vermillion
- Biomarker Novelty & Technology Platform
- Association Studies/Clinical Data
- Management Strategy
- Application & Market Potential
- Biomarker Analysis
- Cancer Biomarker Appendix 1
- Table 8: Global Biomarker Sales 2007-20015e
- Cancer Biomarker Appendix 2
- Table 8: Global Cancer Biomarker Sales 2007-20015e
- Cancer Biomarker Appendix 3
- Company Analysis Criteria
- Biomarker Technology & Platforms
- Association Studies
- Management Strategy
- Application & Potential
- Table 9: Key Cancer Biomarker Companies
- Figure 26: Leading Cancer Biomarker Companies - Service Providers, Technology Providers, Biomarker Discovery & Diagnostic Developers
- Glossary
- Acronyms
- Bibliography & End Notes
- Cns Market & Revenues
- Market Revenues - Global
- Figure 1: Global Cns Drugs Sales (2007)
- Market Revenues - Leading Brands
- Figure 2: Leading Cns Brands (2007)
- Market Revenues - Leading Players
- Figure 3: Top 10 Cns Players (2007 Revenues)
- Market Revenues - Global
- Cns Epidemiology, Diagnosis, Screening & Treatment
- Epidemiology
- Table 1: Cns Statistics For The Most Common Cns Disorders, 2008
- Diagnosis
- Table 2: Indication For Ct And Mri In The Cns
- Screening
- Section Name Cancer, Cns & Cardiovascular Biomarkers: Players, Products And Prospects
- Current & Future Treatment
- Table 3: Classes Of Cns Drugs Approved For Acute And Chronic Conditions
- Future Treatment
- Figure 4: Cns Drugs In Clinical Development
- Epidemiology
- Cns Biomarkers
- Cns Biomarker R&d
- Figure 5: Imaging Biomarkers As Surrogate Endpoints
- Table 4: Types Of Biomarker







